Table 1.
Prevalence of symptoms and signs between exposure and control groups
| 0.42 (0.20-0.88)Symptoms and signs |
Exposure group ) |
Control group |
Relative risk (RR |
| n = 238(%) | n = 212(%) | ||
| Neurastheniaa | 40 (16.81) | 21 (9.91) | 1.74 (1.06-2.58) |
| Pharyngeal irritationb | 138 (57.98) | 63 (29.72) | 1.97 (1.56-2.48) |
| Abnormal ECGa | 24 (10.08) | 40 (18.87) | 0.51 (0.32-0.83) |
| Cholelithiasis | 6 (2.52) | 7 (3.30) | 0.76 (0.26-2.24) |
| Renal cyst | 2 (0.84) | 3 (1.42) | 0.59 (0.10-3.52) |
| Liver ultrasonography abnormalityb | 51 (21.41) | 5 (2.36) | 10.69 (4.38-26.12) |
| Fatty livera | 10 (4.20) | 21 (9.91) | 0.42 (0.20-0.88) |
| Hemoglobin disordersa | 46 (19.33) | 22 (10.38) | 2.07 (1.20-3.57) |
| Hypertension | 11 (4.62) | 15 (7.07) | 0.64 (0.29-1.42) |
| Hepatic hemangioma | 3 (1.26) | 3 (1.42) | 0.89 (0.18-4.37) |
| Leucopenia | 4 (1.68) | 1 (0.47) | 3.61 (0.40-32.53) |
a
P < 0.05 vs control group;
b
P < 0.01 vs control group.